Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.3.1.900
Commitments and Contingencies (Details Narrative)
1 Months Ended 12 Months Ended
Jul. 09, 2015
ft²
Dec. 02, 2014
USD ($)
$ / shares
shares
Sep. 25, 2013
shares
Jul. 30, 2015
USD ($)
kg
$ / kg
Jun. 29, 2015
USD ($)
$ / shares
shares
Apr. 30, 2013
USD ($)
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
Jul. 31, 2015
shares
Jul. 29, 2015
shares
Jul. 24, 2015
USD ($)
$ / shares
shares
Sep. 30, 2013
shares
Common shares issued, par value per share | $ / shares         $ 0.001   $ 0.001 $ 0.001 $ 0.001 $ 0.001        
Lease agreement term               2 years            
Minimum monthly rent               $ 5,000            
Percentage of increase in annual rent               3.00%            
Rent expense               $ 74,000   $ 60,000        
Excersie price per shares | $ / shares               $ 2.250            
Century Park [Member]                            
Lease agreement term 61 months                          
Area of lease | ft² 2,780                          
Months 2 Through 13 [Member]                            
Rent expense               $ 9,174            
Lease term description               months 2 through 13 of the term            
Months 50 Through 61 [Member]                            
Rent expense               $ 10,325            
Lease term description               months 50 through 61            
Annual Excess Milestone Payments [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]                            
Percentage of initial target bonus opportunities of base salary                 3.00%          
Cash bonus                 $ 1,000,000          
Number of stock options expected to vest | shares             6,993 6,993 6,993          
Number of stock options vested | shares                 6,993          
Vesting period of options                 36 months          
Percentage of option vest                 35.00%          
Initial period license payment                 $ 2,000,000          
Ira Ritter [Member]                            
Annual base salary               $ 103,250            
Percentage of initial target bonus opportunities of base salary               35.00%            
Ira Ritter [Member] | Executive Compensation Plan [Member]                            
Annual base salary         $ 295,000                  
Ira Ritter [Member] | 2008 Stock Plan [Member]                            
Options to purchase of common stock shares | shares               48,951            
Andrew Ritter [Member]                            
Annual base salary               $ 124,000            
Percentage of initial target bonus opportunities of base salary               40.00%            
Andrew Ritter [Member] | Executive Compensation Plan [Member]                            
Annual base salary         $ 310,000                  
Tuition reimbursement, payable period         3 years                  
Maximum offer entitled to receive         $ 180,000                  
Paid an aggregate of tuition reimbursement               $ 105,000            
Accrued tuition reimbursement             $ 75,000 $ 75,000 $ 75,000          
Andrew Ritter [Member] | 2008 Stock Plan [Member]                            
Options to purchase of common stock shares | shares               48,951            
Executive [Member] | FDA Meeting Bonus Opportunities [Member]                            
Cash bonus           $ 10,000                
Executive [Member] | Clinical Trial Funding Commitment Bonus Opportunities [Member]                            
Cash bonus               $ 75,000            
Number of stock options expected to vest | shares                       3,671    
Number of stock options vested | shares               10,489            
Stock options to vest ratably on a monthly basis | shares                     6,818      
Vesting period of options               36 months            
Minimum actual deployment of funds by third party               $ 2,000,000            
Percentage of option vest               35.00%            
Bonus received               $ 75,000            
Executive [Member] | Fundraising Bonus Opportunities [Member]                            
Cash bonus               50,000            
Minimum actual deployment of funds by third party               $ 2,000,000            
Executive [Member] | License Event Bonus Opportunities [Member]                            
Percentage of initial target bonus opportunities of base salary                 35.00%          
Number of stock options expected to vest | shares             45,454 45,454 45,454          
Number of stock options vested | shares                 45,454          
Vesting period of options                 36 months          
Minimum upfront payment of license                 $ 2,000,000          
Initial period license payment                 $ 2,000,000          
Executive [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]                            
Number of shares called by options | shares             48,951 48,951 48,951          
Number of stock options expected to vest | shares             27,972 27,972 27,972          
Percentage of initial period license payment                 5.00%          
Initial period license payment                 $ 5,000,000          
Executive [Member] | Executive Options [Member] | FDA Meeting Bonus Opportunities [Member]                            
Number of stock options expected to vest | shares     3,496                      
Number of stock options vested | shares     2,360                      
Stock options to vest ratably on a monthly basis | shares                           1,136
Executive One [Member] | Fundraising Bonus Opportunities [Member]                            
Cash bonus               $ 150,000            
Minimum actual deployment of funds by third party               $ 10,000,000            
Executive One [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]                            
Percentage of initial period license payment             4.00%              
Executive One [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member] | Minimum [Member]                            
Initial period license payment                 5,000,000          
Executive One [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member] | Maximum [Member]                            
Initial period license payment                 $ 10,000,000          
Executive One [Member] | Executive Options [Member] | Fundraising Bonus Opportunities [Member]                            
Percentage of initial target bonus opportunities of base salary             35.00% 35.00%            
Number of stock options expected to vest | shares             6,993 6,993 6,993     4,895    
Number of stock options vested | shares             13,986 6,993            
Stock options to vest ratably on a monthly basis | shares                     9,091      
Vesting period of options             36 months 36 months            
Bonus received               $ 150,000            
Proceeds from issuance of shares upon closing of initial public offering               17,400,000            
Executive Two [Member] | Fundraising Bonus Opportunities [Member]                            
Minimum actual deployment of funds by third party               $ 2,000,000            
Executive Two [Member] | Compensation Plan [Member] | License Event Bonus Opportunities [Member]                            
Percentage of initial period license payment                 3.00%          
Initial period license payment                 $ 10,000,000          
Amended Clinical Supply And Cooperation Agreement [Member] | Ricerche Sperimentali Montale Spa And Inalco Spa [Member]                            
Further option payment due in future                         $ 1,000,000  
Number of common shares to be issued | shares             100,000 100,000 100,000       100,000  
Common shares issued, par value per share | $ / shares                         $ 0.001  
Fair value of shares to be paid             $ 416,000 $ 416,000 $ 416,000          
Amended Clinical Supply And Cooperation Agreement [Member] | Ricerche Sperimentali Montale Spa And Inalco Spa [Member] | Contractual Rights [Member]                            
Payment for GOS IP       $ 800,000                    
Payment required following FDA approval to RSM       $ 400,000                    
GOS kilograms | kg       350                    
GOS price per kilo | $ / kg       250                    
GOS price per kilo under existing supply agreement (in dollars per kilo) | $ / kg       2,000                    
Step Letter Agreement [Member] | Chief Executive Officer [Member]                            
Annual base salary   $ 360,000                        
Step Letter Agreement [Member] | Chief Executive Officer [Member] | Employee Stock Option [Member]                            
Number of shares called by options | shares   646,537                        
Excersie price per shares | $ / shares   $ 5.86                        
Description of right to repurchase lapse   1/44th of the total number of shares subject to the right of repurchase                        
Step Letter Agreement [Member] | Chief Executive Officer [Member] | Employee Stock Option Two [Member]                            
Number of shares called by options | shares   73,377                        
Excersie price per shares | $ / shares   $ 5.86                        
Description of right to repurchase lapse   1/44th of the total number of shares subject to the right of repurchase                        
Step Letter Agreement [Member] | Chief Executive Officer [Member] | Employee Stock Option Three [Member]                            
Number of shares called by options | shares         163,799                  
Percentage shares of common stock deemed to be outstanding         7.50%                  
Description of right to repurchase lapse         1/36th of the total number of shares subject to the right of repurchase